Endo, Blaise Coleman
Blaise Coleman, the current EVP and CFO of Endo, will succeed Paul Campanelli in the position of the company’s president and CEO, concurrently becoming a member of the board of directors, the company announced towards the end of February.
The appointment, which will take effect on March 6, 2020, is a result of Campanelli’s retirement, after five years of joining Endo with the acquisition of Par Pharmaceutical.
Coleman has more than 20 years of experience in the pharmaceutical industry. Prior to joining, he held a number of leadership roles with AstraZeneca and Johnson & Johnson, after beginning his career at PricewaterhouseCoopers.
In his current role, Coleman will be succeeded by Mark Bradley, Endo’s SVP of Corporate Development & Treasurer. Bradley has been with Endo since 2007, holding several financial and strategic development leadership positions, after having worked with Deloitte and Ernst & Young.